

Adherence: Successful therapy

By Kimberly Scarsi

NTIRETROVIRAL therapy offers highly effective and successful treatment for patients infected with HIV. The combination of these medications has consistently demonstrated durability over the past decade. However, the role of the patient in this success is vital. Patient adherence to the prescribed antiretroviral combination is known to improve viral suppression, slow progression to AIDS, and is considered a cornerstone in preventing the development of antiretroviral resistance.¹

Ensuring that all patients initiating an antiretroviral combination understand the importance of adherence as part of their overall programme is an important component of the care of HIV-infected patients.

Commonly quoted statistics based on data collected during the late 1990s estimate that a minimum of 95% adherence is desired to ensure a successful antiretroviral treatment.² These data were based on available antiretroviral therapies available at that time, specifically two nucleoside reverse transcriptase inhibitors (NRTIs) plus a protease inhibitor (PI), often dosed thrice daily. Over the past several years, other antiretroviral strategies have become more commonly employed, such as nonnucleoside reverse transcriptase inhibitors (NNRTIs) and boosted PIs, allowing for less frequent dosing.

Accumulating data have suggested that the level of




Figure 1 Schematic figure outilining the relationship between medication adherence and the risk of developing PI or NNRTI drug resistance, NNRTI-treated individuals rarely develop resistance at high levels of adherence due to the virological effectiveness of these regimens. NNRTI resistance develops rapidly at moderate to low levels of resistance due to the low 'fitness' costs associated with single mutations, Single PItreated individuals may develop resistance at high levels of adherence because residual viral replication is often seen in such patients. PI resistance is uncommon at low levels of adherence because of the significant fitness costs associated with these mutations, Resistance to a ritonavir-boostedPI is only possible in a narrow range of adherence where there is suffident drug around to select for mutations that reduce 'fitness' while still allowing residual viral replication. Data in this figure are conceptual and based on trends observed in a number of recent studies (see text). PI, protease inhibitorm, NNRTI, nonnucleo side revete transcriptase inhibitor.

adherence that is required to prevent the development of drug-resistant virus is a complex relationship and may be related to the combination therapy being used. For nonboosted PI-based therapies, patients who take most of their doses of medications, approximately 70-80%, may have an increased risk of drug-resistant virus as compared to those patients who are highly adherent or very poorly adherent. Boosted PI regimens may have an overall lower risk of developing risk at any adherence level, with the greatest risk of resistance at approximately 50% adherence. Finally, NNRTIbased regimens will likely result in the development of few resistance mutations in any patient who is highly adherent, but will easily

develop resistance in the presence of any viral replication. See Figure 1 for a visual interpretation of these data from Bangsberg et al.¹

Regardless of the exact adherence required, these data still suggest that care providers and patients should be striving for as close to 100% adherence as possible to ensure therapeutic success. Because of this large commitment the patient is undertaking at the beginning of antiretroviral therapy, it is essential to ensure the patient possesses the motivation to make this therapy successful. Engaging the patient in the reasons that adherence is necessary, as well as the implications of non-adherence will help them understand their role in making antiretroviral drugs work for them.

Ensuring the patient understands the dose, frequency, timing of medications with food or at certain times of day is crucial at the initiation of therapy. Also, explaining potential side effects, and management of these side effects, will help the patient overcome the initial difficulty with starting these regimens.

Consistent reinforcement of adherence from physicians, nurses, counsellors, and pharmacists at each clinic visit will help ensure the patient understands the importance of this aspect of care. Finally, including any patient support system, friends, family, or neighbours, in the reinforcement of the importance of medication adherence will help keep the patient motivated between clinic visits and provide the much needed support for the patient throughout therapy.³ References

1.Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Ther 2004; 53:696-699. 2.Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30. 3.Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. JAIDS 2002; 31(Suppl 3):S154-S157.

The writer is a HIV Clinical and Research Pharmacist Northwestern Memorial Hospital Chicago, IL

<u>From The ATIC News</u>

P. O. Box 22418, Kampala, Uganda.Tel (queries): 256-31-307245/ 307228.Tel (admin.): 256-41-542352/ 542283; website:www.atic-africa.org

EDITORIAL BOARD

Editor

Ms Barbara Bitangaro BA Lit (Hons), MPH **Advisors** Dr Mairin Ryan HIV pharmacist and Health economist, Trinity College Dublin Dr Ceppie Merry HIV physician and pharmacologist, Trinity College Dublin Professor Allan Ronald Member ATIC PWG Dr Cissy Kityo Deputy Director Joint Clinical Research Centre Mr Paul Kagwa Asst. Commissioner Health Services, HED, Ministry of Health Kim Scarsi, HIV Clinical and Research Pharmacist. Northwestern Memorial Hospital Illinois, Chicago

ATIC is located on 1st floor Makerere University Institute of Public Health, Mulago Hospital. ATIC acknowledges the support of Roche, Makerere University, Mulago and all its partners

Resistance testing for HIV disease

A very happy new year to all the friends of ATIC. We look forward to another year of working with you to help fight HIV/AIDS in Africa. This year we have some new and exciting ideas for the ATIC newsletter which we will share with you during the year. In this month's newsletter we are privileged to have an article from Dr Jonathan Schapiro on resistance testing for HIV disease. Dr Schapiro is a key opinion leader in this field and has particular interest in the interaction between resistance testing and pharmacokinetics. Dr Schapiro provides an excellent overview on the two types of resistance testing that are currently available- genotyping and phenotyping. However, both tests are very expensive and are by no means required for antiretroviral drugs to be used. Good clinical judgement


is paramount to this. These tests should be seen as an adjuvant to further improving patient care. Like any clinical investigation, these tests should be interpreted properly and used with caution considering their limitations. Resistance testing needs to be combined with proper clinical education and quickly made available worldwide. As healthcare providers our job is to minimise the emergence of resistance by counselling patients on adherence and watching out for drug interactions which could inadvertently expose patients to sub-therapeutic drug levels. Even if a patient is 100% compliant, the patient will develop resistance if the doctor adds in TB therapy and forgets to adjust the dose of the antiretrovirals. It is hard to constantly watch for drug-drug interactions as these

can happen with drugs that our patients are taking for diseases other than HIV and may not even be prescribed by us. A prominent feature in the prevention of development of resistance is excellent management of the drug supply, storage and distribution and we will be doing an special ATIC newsletter dedicated to this later this year. Another article in this issue highlights the need to integrate the practice of clinical pharmacology into HIV/AIDS patient care in the choice of antiretroviral drug regimens by focusing on Tenofovir (TDF) and didanosine (DDI), the most frequently prescribed nucleoside analogues. We have also taken the opportunity to provide you with protease inhibitor (PI) and non-nucleoside reverse transcriptase nihibitor (NNRTI) charts that you can use daily.

UN calls for more effort to halt HIV

HERE is new evidence that adult HIV infection rates have decreased in certain countries and that changes in behaviour to prevent infection—such as increased use of condoms, delay of first sexual experience and fewer sexual partners—have played a key part in these declines. The new UN report also indicates, however, that overall trends in HIV transmission are still increasing, and that far greater HIV prevention efforts are needed to slow the epidemic.

Kenya, Zimbabwe and some countries in the Caribbean region all show declines in HIV prevalence over the past few years with overall adult infection rates decreasing in Kenya from a peak of 10% in the late 1990s to 7% in 2003 and evidence of drops in HIV rates among pregnant women in Zimbabwe from 26% in 2003 to 21% in 2004. In urban areas of Burkina Faso prevalence among young pregnant women declined from around 4% in 2001 to just under 2% in 2003.



Doctors discuss ways of tackling HIV

These latest findings were published in *AIDS Epidemic Update 2005*, the annual report by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO). The joint report focuses on HIV prevention

Several recent developments in the Caribbean region (in Bahamas, Barbados, Bermuda, Dominican Republic and Haiti) give cause for guarded optimism—with some HIV prevalence declines evident among pregnant women, signs of increased condom use among sex workers and expansion of voluntary HIV testing and counselling.

Despite decreases in the rate of infection in certain countries, the overall number of people living with HIV has continued to increase in all regions of the world except the Caribbean. There were an additional five million new infections in 2005. The number of people living with HIV globally has reached its highest level with an estimated 40.3 million people, up from an estimated 37.5 million in 2003. More than three million people died of AIDS-related illnesses in 2005; of these, more than 500000 were children.

Efavirenz: Its use with other ARVs

Francis Kalemeera, BPharm, BSc, MPS discusses efavirenz and its use

Indications and pharmacological class ^{1,9}

Efavirenz (EFV), also called Sustiva® or Stockrin®, is a synthetic antiretroviral agent belonging to the Non Nucleoside Reverse Transcriptase Inhibitors' (NNRTI) class. It is used in combination with other antiretroviral agents for the treatment of HIV type 1 infection. Efavirenz may also be used as one of the drugs in the regimen for post exposure prophylaxis: i.e. a basic two drug regimen (2NRTI) plus efavirenz. **Dosage and Administration**

1,2,11

Efavirenz should be taken on an empty stomach, preferably in the evening just before bedtime. Increased serum concentrations have been noted when efavirenz is taken with food, which may be associated with an increase in adverse effects. **1. Tablets**

Adult and Adolescent over 12 years, = 40kg: 600mg once daily

2. Capsules

Adult and child over 3 years, based on weight (kg):

 10 to < 15kg: 200mg once daily

 15 to < 20kg, 250mg once daily

 20 to < 25kg, 300mg once daily

 25 to < 33kg, 350mg once daily

 33 to < 40kg, 400mg once daily = 40kg, 600mg once daily

3. Oral Solution (30mg/ml) Note that the bioavailability of the oral solution is lower than that of the capsules and tablets, thus the difference in the dosage schedule below. Adult and child over 3 years, based on weight (kg):

10 to <15kg, 270mg (=
9ml) once daily
15 to < 20kg, 300mg (=

• 15 to < 20kg, 300mg (-

Cut here

10ml) once daily

- 20 to < 25kg, 360mg (= 12ml) once daily
- 25 to < 33kg, 450mg
- (=15ml) once daily • 33 to < 40kg, 510mg (=
- 17ml) once daily • = 40kg, 720 mg (= 24ml) once daily

Adverse Drug Reactions 2,3,6

The most frequently reported side effects associated with efavirenz in combination with other anti-HIV medications include rash and nervous system symptoms that include dizziness, insomnia or somnolence, impaired concentration and abnormal dreams. Generally symptoms are worse after the 1st and 2nd doses and improve over 2-4 weeks. Dosing of efavirenz at bedtime, as well as in a fasting state. may help to improve tolerability of the medication and should be recommended. The rash generally presents as a maculopapular skin eruption during the first two weeks after initiating therapy. In most cases, the rash resolves with continued efavirenz use; however, efavirenz should be discontinued if the rash is severe. Other reported adverse effects include nausea, vomiting, diarrhea, hepatitis, allergic reactions, abdominal pain and raised serum cholesterol.

Contraindications and Precautions ^{5,7}

Efavirenz use should be avoided during pregnancy unless the potential benefit justifies potential risk to the foetus, for example in pregnant women without other therapeutic options after the first trimester of pregnancy. The pregnancy category for efavirenz was recently changed from Category C (Risk of fetal Harm Cannot Be Ruled Out) to Category D (Positive Evidence of Fetal Risk).

Barrier methods should always be used in combination with other contraceptive methods in patients taking efavirenz. Efavirenz is contraindicated in patients with clinically significant hypersensitivity to it and to any of the components of the formulation.

Monitoring parameters 7 Monitor liver enzymes (AST and ALT) and cholesterol levels in plasma. Some patients accidentally taking 600mg twice daily have reported increased nervous system symptoms. 10

Drug Interactions 8

Because efavirenz is an inducer of cytochrome P450 (CYP) 3A4, other compounds that are substrates of this enzyme may have decreased plasma concentrations when co-administered with efavirenz. For example, efavirenz decreases the lopinavir concentration when the two drugs are given concomitantly. Therefore, patients on efavirenz and lopinavir/ritonavir (Kaletra®) should increase the Kaletra® dose to four capsules (533/133mg) twice daily.

Additionally, in vitro efavirenz has been shown to also inhibit CYP 2C9, 2C19, and 3A4 enzymes, potentially resulting in an increase in the plasma concentration of medications metabolized by these enzymes.

Examples include: bepridil, dihydroergotamine, ergotamine, ergometrine, terfenadine, pimozide, midazolam, triazolam and cisapride. These drugs should not be administered together with efavirenz.

Dosing in renal insufficiency and hepatic impairment ⁸

The pharmacokinetics of efavirenz in renal and hepatic impairment has not been adequately investigated. Less than 1% of efavirenz is excreted unchanged in urine, thus renal impairment is unlikely to have a significant effect on efavirenz pharmacokinetics. However, efavirenz is extensively metabolized by the liver so caution should be used when using efavirenz in patients with underlying hepatic impairment. Storage ^{3,7}

Efavirenz preparations should be stored at 15 - 30oC and kept out of reach of children.

Presentations 1-4

Efavirenz is available as: capsules of 50mg, 100mg and 200mg; film coated tablets of 600mg; and an oral solution containing 30mg/ml.

References

1.Monograph-Efavirenz, Available on http://www.medscape.com

2. The British National Formulary 48, September 2004, Section 5.3.1, Nonnucleoside reverse transcriptase inhibitors, Page 316 3.STOCRIN® Package leaflet, Merck Sharp and Dohme B.V. Post bus 581, NL-2003, PC Haarlem

4.Douglas L. Mayers, Efavirenz : In AIDS Therapy 2nd Edition, 2003 page 145 5.Efavirenz warning in pregnancy strengthened, Available on http://www.i-base.org.uk 6.Merle A. Sande, Robert C. Moellering, David N. Gilbert, The Sanford Guide to HIV/AIDS Therapy, Twelfth Edition, 2003 page 24 7.Information for Health Professionals, STOCRIN® Data Sheet, Available on http://www.medsafe.govt.nz 8.Drug Interaction Charts, The University of Liverpool, Available on http://www.hivdruginteractions.org 9.Monica Preboth, PHS Guidelines for Management of Occupational Exposure to HBV, HCV and HIV: Post exposure Prophylaxis Regimens, Available on http://www.aafp.org 10.STOCRIN® available on www.msd-gulf.com 11.World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach-2003 update. Available at http: //www.who.int/hiv/pub/prev_car e/en/arvrevision2003en.pdf.

Tenofovir and Didanosine; the combination to watch

OME of the goals of antiretroviral therapy are to achieve viral suppression and improve the immunological functions of the patient's body. The combination of drugs work together to ensure that the virus levels are reduced to undetectable levels and that there is an increase in the CD4 cells. Tenofovir (TDF) and didanosine (DDI) are among the most frequently prescribed nucleoside analogues (NA) because both are administered in a convenient fashion, show relatively high genetic barrier for resistance, have a quite acceptable safety profile, and remarkable antiviral potency. However, their co-administration has caused concern given the recent evidence of unexpected CD4 T-cell declines in patients treated with this dual NA combination despite having undetectable viral load ^{1, 2}. At the same time, several reports have highlighted an increased risk of pancreatitis and of hyperglycemia in patients treated with TDF plus DDI 3-5.

In a large multicentre study the CD4 cell outcome in patients receiving different NA combinations, including TDF plus DDI, DDI alone, TDF alone, and others was assessed. A new mechanism, by which TDF plus DDI may cause CD4+ T-cell depletion in HIV-infected individuals despite providing complete virus suppression, was proposed [6].

At 12 months, the median CD4 T-cell counts was significantly lower in patients included in the simplification on TDF + DDI when compared to those taking DDI or TDF alone. Moreover, in drug-naive individuals, those under DDI + TDF experienced a significantly lower gain in the median CD4+ T-cell count when compared with patients in other groups, taking either DDI or TDF. This occurred in drugnaive and simplified patients irrespective of the third agent included in the triple combination.

This study demonstrates that HIV-infected individuals receiving DDI + TDF-based combinations show CD4 T-cell declines (in both absolute number and percentages) despite complete virus suppression. This effect generally occurs after 6 months of therapy and worsens with time. It occurs earlier and is more pronounced when TDF + DDI are taken together with another NA as third agent as well as when using high **Robinah Nganwa** highlights the need to integrate the practice of clinical pharmacology into HIV/AIDS patient care in the choice of antiretroviral (ARV) drug regimens. Increased collaboration between pharmacists and doctors in making decisions concerning drug therapy will maximise prescribing of ARV drugs.

DDI doses. Accordingly, high DDI plasma levels correlated with loss of CD4 T cells. Finally, CD4 T-cell declines were not seen in patients receiving any other antiretroviral regimen, including those in which either TDF or DDI were included. Given that DDI and TDF are both adenosine analogues, it is hypothesized that a synergistic effect of their metabolites might cause an imbalance in the purine pool within CD4 T lymphocytes. As these cells experience a rapid turnover in HIV infection, any impairment in cell replication might translate into loss of CD4 T cells by a mechanism which is independent of virus replication. This cytostatic effect of TDF + DDI combinations on CD4 T lymphocytes essentially resembles the T-cell immunodeficiency seen in the purine nucleoside phosphorylase (PNP) deficiencv. a rare autosomal recessive genetic disorder ⁷⁻⁹. The homozygotes present as severe combined immunodeficiency, with recurrent infections and death in infancy.

ailure to clear purine metabolites and accumulation of deoxyquanosine-triphosphate (dGTP) in these children result in an inhibition of the ribonucleotide reductase enzyme, which in turn, inhibits DNA synthesis and impedes cell division. Although the PNP enzyme is found in most body tissues, it has the highest levels in lymphoid cells, which may explain why CD4 T lymphocytes are selectively targeted in HIV-infected patients receiving DDI and TDF together. It is the hypothesis that because TDF metabolites inhibit PNP 10. the use of the alternative purine pathway by DDI metabolites is compromised in HIV-infected individuals on DDI + TDF. There is a shift to production of high levels of dGTP, which results in an inhibition of the ribonucleotide reductase, and consequently DNA synthesis is blocked, causing CD4 T-cell declines. The fact that CD4+ Tcell declines were generally seen after 6 months on DDI + TDF therapy suggest that some compensatory mechanisms are involved, at least in the short term, which ultimately fail as extended periods of therapy are given.

In the study above, the greater CD4 Tcell decline seen in patients who took DDI + TDF with a third NA is a remarkably finding. The fact that other triple NA combinations did not cause CD4 T-cell drops, including those in which TDF or DDI were provided separately, suggests that administration of additional NA's might further exacerbate the metabolic interaction between DDI and TDF within the cells.

These findings are relevant for selection of antiretroviral combinations and discourage the use of TDF and DDI in combination. The recognition of CD4 T-cell declines in patients taking these medications together adds to the other recently discussed concerns about other side effects, including a higher risk of pancreatitis, hyperglycemia, and lactic acidosis, as well as of higher risk of virological failure with selection of the K65R mutation. Therefore, when possible, the combination of TDF and DDI should be avoided.

From a public health point of view, this issue is of great concern in developing countries where patients are initiated on antiretroviral therapy at relatively lower CD4 counts. Anything that acts to decrease the already low CD4 values or that slows the increase in CD4 values should be avoided. There is therefore a need to review current policies in several countries that have put the combination of TDF + DDI on national programs.

References

1. Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir based regimens despite undetectable viral load. AIDS 2004; 18:459-463.

2. Negredo E, Bonjoch A, Paredes R, Clotet B. Concurrent administration of tenofovir and didanosine compromises immunologic recovery in treatment-experienced patients. Results from the TORO



QUESTIONS *with* Robinah Nganwa

After diagnosing KS in an HIV patient and putting them on vincristine and bleomycin, which lab parameter should we monitor regularly?- J.G, Uganda

Because chemotherapeutic agents adversely affect bone marrow cells, a complete blood count (CBC) is necessary prior to each treatment. The effects on bone marrow are temporary and normal functioning usually returns within 4-10 days. Because mature red blood cells have a relatively long life (120 days), cell production usually resumes before symptoms of deficiency develop. White blood cells (WBC), however, have a life span of 1 to 3 days only. Those in circulation remain unaffected, but the production of new leukocytes may be slow, creating a period of increased risk for infection. WBC production usually recovers before the next treatment. If it does not, treatment is delayed until the cell count increases sufficiently. Thrombocytopenia (below normal platelet count of 15,000 to 300,000 per milliliter) and the risk of increased bleeding usually peaks 10 to 14 days following a course of chemotherapy. Damage to these cells is not permanent. Normal values WBC- 2.75-7.7 x 103 /uL **RBC** count Men: 4.7-6.6 x 106 /uL Women: 4-5.6 x 106 /uL hHeamoglobin Men: 14.4-18.9 g/dL Women: 10.9-16.7g/dL Platelet count Men: 156-358 x 103 /uL Women : 125-445 x 103 /uL

ICASA: Switching therapy

HE 14th International Conference on AIDS and Sexually Transmitted Infections in Africa was held December 4 to 9 2005 at Abuja, Nigeria. The following is an overview of two presentations delivered at the conference.

Hope for a preventive vaccine for HIV

Professor Robert Gallo of the Institute for Human Virology, renowned for his work in the discovery of HIV as the cause of AIDS along with Luc Montagnier made a presentation on the history of the HIV epidemic and prospects for developing a preventive HIV vaccine.

According to Gallo, "the multiple mechanisms evolved by HIV to impair the immune response is in itself a warning against the use of "live" attenuated HIV vaccine strategies". This among other difficulties has hampered efforts at developing an effective vaccine. He presented current research which demonstrated effectiveness of cross linked Gp120-CD4 complexes in eliciting



Gallo co-discovered the HIV

antibody responses that neutralise diverse primary isolates of HIV within and across clades.

Feasibility of switching to boosted PIs in Africa

Dr Cisse Mamadou described the NOGOMA study (a prospective monocentre study) giving twelve month results of a boosted PI strategy with Indinavir (IDV)/ritonavir(r) 400mg/100mg in Bamako Mali.

The aim of this study was to assess the feasibility, efficacy and safety of switching from IDV 800mg Tid and two NRTIs to IDV/r 400/100mg Bid and the same NRTIs in HIV-1 infected patients.The feasibility of switching to a boosted protease inhibitor regimen in Africa had been questioned due to lack of refrigerator facilities for drug storage and high local temperatures which can exceed 40 degrees Celsius in some countries. In this study, 60% of patients had access to a refrigerator; other patients used traditional methods of keeping food and water cool.

All patients had been on the previous indinavir based regimen for 12 months. Following the switch to indinavir boosted with ritonavir, there was an increase in median CD 4 count from 244 to 321cells per microlitre and 93% versus 83% attaining a viral load less than 400 copies per ml at week 48. There was no incidence of grade >2 adverse reactions and none of the patients was lost to follow up.

There were no significant differences in results according to mode of storage of indinavir boosted with ritonavir with respect to immunologic, virologic and pharmacokinetic parameters; leading to the conclusion that boosted indinavir is a feasible option in Africa despite local conditions.

The TDF and DDI combination

From page 4

studies. Seventh International Congress on Drug Therapy in HIV Infection, Glasgow; November 2004 [abstract PL3].

 Martinez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco JL, Larrousse M, et al.
 Pancreatic toxic effects associated with coadministration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364:8-10.
 Kirian M, Higginson R, Fulco P. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Ann Pharmacother 2004; 38:1660-1663.

5. García-Benayas T, Barrios A, Sánchez-Conde M, Rendón A, R-Nóvoa S, Sánchez-Somolinos M, et al. Higher risk of hyperglycaemia in patients under didanosine and tenofovir-containing regimens. In: Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. February 2005 [abstract 197] . 6. AIDS. 2005 Mar 24;19(6):569-75.

7. Cohen A, Doyle D, Martin D, Ammann A. Abnormal purine metabolism and purine over production in a patient deficient in purine nucleoside phosphorylase. N Engl J Med 1976; 295:1449-1454.

8. Myers L, Hershfield M, Neale W, Escolar M, Kurtzberg J. Purine nucleoside phosphorylase deficiency (PNP-def) presenting with lymphopenia and developmental delay: successful correction with umbilical cord blood transplantation. J Pediatr 2004; 145:710-712.

9. Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev 1991; 3:45-81.

10. Ray A, Olson L, Fridland A. Role of purine nucleoside phosphorylase interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-1095.

The selection of drug

By Jonathan M Schapiro, MD

IV has a very high potential to mutate. Although this results in generation of a large amount of non-viable virus, it also allows HIV many opportunities to select for genetic changes that code for viral target proteins less susceptible to antiretroviral drugs. These are drug resistance mutations. If selective pressure is exerted by drug therapy (in other words, viruses with resistance mutations to the drug will replicate better than those without) and the virus continues to replicate (incomplete viral suppression), eventually viruses with resistance mutations will emerge and populate the host out-competing the original wild type virus.

To prevent resistance we either need to avoid selective pressure (not give drugs) or prevent replication (complete viral suppression with our drugs). If we treat with drugs and the virus is allowed to replicate, we will be selecting for resistant virus with drug resistance mutations.


Only viruses with reduced susceptibility to the drug (or drugs) will have a selective advantage and not be inhibited. If drugs are used in combination, especially if for some of the drugs multiple mutations are required for resistance; it will be hard for the virus to select a virus with all the required mutations. If a virus with only one or two relevant mutations appears, it will still be inhibited with equal efficacy and not have a selective advantage and replicate.

Thus the advantage of using drugs requiring multiple mutations for resistance, and of course, of using drugs in combination. The numbers of mutations by a drug, or a drug regimen, required for resistance is sometimes referred to as the "genetic barrier".

Cross-Resistance


When failing a drug the virus selects for mutations that confer resistance (or reduced susceptibility) to the drug. Commonly these mutations also effect other drugs of the same class (NRTI. NNRTI or PI) that interact with the target protein in a similar fashion. This phenomenon known as "cross-resistance" is key to the utility of drug resistance testing. If drugs selected only for mutations that affected themselves, treatment history alone would be sufficient to guide our therapeutic decisions when changing therapy in a failing patient. Understanding which mutations effect which drugs, and to what degree, is at the core of our ability to predict drug resistance. Although drugs may commonly select for a specific mutation. many other mutations or combinations of mutations may also confer resistance to the drug. Knowing all these different patterns that confer resistance to the drug is crucial for pro per interpretations of resistance assays. An example might be the protease inhibitor nelfinavir. This drug commonly selects for mutations D30N or L90M that confer resistance to it, but is also strongly effected by mutation I84V selected by other PI.

Drug Resistance Assays There are two types of assays used to determine antiretroviral drug resistance. The first is known as a genotypic assay and it examines the genetic makeup of the virus. The basis of resistance is of course the mutations in the viral genes that code for the proteins targeted by the drug. Changes in the genetic sequence result in changes in the target protein (for example



the protease enzyme's active site) and thus determining these changes allow us to assess drug resistance. Genotypic assays are performed by taking a small amount of patient blood and amplifying the viral RNA by molecular techniques (PCR). The genetic code of the relevant genes is determined (RT and protease) and drug resistance mutations are identified. An interpretation system that links specific mutations or patterns of mutations with resistance to the different drugs is then used to determine which drugs are resistant, partially resistant, or remain susceptible. Genotypic resistance assays are the most commonly used, and by far the most experience worldwide is with these assays. Multiple studies have shown their clinical utility, although they must be used wisely by clinicians understanding their limitations and proper interpretation of the assay results is crucial.

Phenotypic, or susceptibility assays are the second type of resistance assay. Here a laboratory test is performed to evaluate how resistant the specific virus is to each drug. The entire virus is not tested, only the area of the virus that determines the




RT and protease enzymes (and some surrounding genes). Here too, initially the viral RNA is amplified and then inserted into a specifically genetically engineered test virus. These assays are only performed on a large scale at a few laboratories around the world, mostly private companies. They require extremely expensive laboratory facilities and take longer and are considerably more expensive (~1,000 US Dollars for each blood sample) than genotypic tests (usually ~ 200 - 400 US Dollars). There are less data on the utility of phenotypic assays as routine clinical tools. Since they are not nearly as available


Understanding which mutations effect which drugs, and to what

resistance by HIV

Drug Resistance Assays Must Predict Clinical Resistance



Suppress viral replication in the patient



as genotypic assays, take longer and are more expensive, and have never been found to have any advantages over genotyping; phenotypic assays are used worldwide much less often than genotyping which has become by far the more commonly used test. Phenotypic assays are a very important research tool and are key to understanding the resistance characteristics of new drugs. Although there is hope that perhaps these assays will have an advantage in highly drug-experienced patients, no studies thus far have shown this to be true.

Clinical Utility of Resistance Testing

Clinicians must always keep in mind that resistance assays can help us decide which drugs will likely not work against the patients virus, or will have reduced activity, but can not decide for us which drugs are best to use. Therefore the main use of these assays is to rule out drugs, not rule them in.

Resistance assays must always be used to augment good clinical judgment and experience, never replace them. It is important to consider the many limitations of resistance assays, and to incorporate their results only in the context of the specific patient. Since drug resistance assay results may not show resistance to drugs the patient has failed in the past and is no longer receiving, it is imperative that we consider the patients previous drug history in addition to the assay results before making treatment decisions. Let's for example consider a patient who received many years ago a protease inhibitor containing regimen. Upon failing the PI, he was switched to an NNRTI based regimen for a number of years. Now the patient is failing the NNRTI regimen and we perform a resistance assay. Since there has

been no selective pressure by a PI on the virus for years, the PI mutations that were selected in the past may no longer be detectable on the resistance assay - even thought they remain present in the patient at low levels and will quickly reemerge if a PI is administered. Thus we must consider previous history, the presumed causes of failure, and the resistance assay results in order to rule out drugs properly. Of the drugs judged to still be active by these considerations, we must choose the regimen we believe will both be potent and best tolerated and convenient for the patient.

Resistance assays commonly provide three levels of interpretation for each drug. Based on the mutations present, a drug is considered as either susceptible, partially resistant, or resistant. Many alternative terms are also used (please see figure XX). "Susceptible" implies that the drug will maintain antiviral activity similar to a virus without any mutations, or have full activity. "Resistant" defines drugs with minimal to no activity, and "partially resistant" is used for drugs who will maintain significant activity, but it will be substantially less than would be expected of the drug if no mutations were present.

Comments to note

Drugs considered resistant by the assay, may still maintain some inhibitory effect on viral replication. This has been found to be true for both the NRTI and PI. but not for the NNRTI. It is thought that perhaps the mutations conferring resistance to the NRTI or PI also compromise the ability of the viral enzyme to function properly, thus reducing viral replication. Alternatively the dugs may still have some activity despite widespread resistance. Therefore clinicians often

continue to treat with NRTI and PI despite assay results showing resistance to all the drugs of the class. This often results in HIV RNA viral load levels 0.5 -1.0 log less than would be seen without therapy and may preserve immune function, at least for some period of time

The interpretation of resistance assay results in by no means perfect. Interpretations of both the genotypic and phenotypic assays change and are updated and improved all the time. One must realize this limitation of resistance assays and not assume perfect accuracy from the results. Interpretation of NRTI resistance is most challenging and determining which NRTI maintains activity in a patient with many mutations may not be always accurate for either of these types of assays.

Some interpretation systems, like the Stanford database, report more than three levels of resistance, dividing partial resistance into three different groups.

Summary

Resistance assays are an important tool assisting clinicians in optimizing antiretroviral drug choices. Genotypic assays have gained widespread use in countries with sufficient resources. These assays are by no means a requirement for antiretroviral drugs to be used, and good clinical judgment and experience are far more important. These assays should be seen as an adjuvant to further improving patient care. Resistance assays must always be interpreted properly, and used with caution considering their limitations. They need to be combined with proper clinician education and quickly made available worldwide.

National Hemophilia Center, Tel Aviv, Israel

at degree, is at the core of our ability to predict drug resistance

ATIC News, Vol 2, Issue 3

COMMENTARY

IN BRIEF

Migrants

Both Mexicans who migrate to the United States for work as well as many Mexican migrants returning home are increasingly engaging in high-risk behaviors that put these groups at heightened vulnerability to HIV infectionespecially since they are often outside the reach of conventional HIV prevention programs. Two new studies from the California-Mexico AIDS Initiative—a joint program coordinated by the Mexican Secretariat of Health and the University of California Office of the President—show rising rates of HIV infection among Mexican migrants within Mexico and in California.

HIV in China

China faces important challenges as it strives to contain a large and growing HIV/AIDS crisis that experts fear could affect more than 10 million people there by 2010. While The epidemic—which had initially centered among intravenous drug users and former plasma donors is exploiting new opportunities for transmission to take place through heterosexual sex and sex between men.

PLWHA more

Despite decreases in the rate of infection in certain countries, the overall number of people living with HIV has continued to increase in all regions of the world except the Caribbean. There were an additional five million new infections in 2005. The number of people living with HIV globally has reached its highest level with an estimated 40.3 million people, up from an estimated 37.5 million in 2003.




A HIV patients (centre), with her attendants waits for care at a hospital

The heart of the health system

By Dr Tim Evans

EALTH workers - the people who provide health care to those who need it - are the heart of health systems. But around the world, the health workforce is in crisis - a crisis to which no country is entirely immune. The results are evident: clinics with no health workers, hospitals that cannot recruit or keep key staff.

There is a chronic global shortage of health workers, as a result of decades of underinvestment in their education, training, salaries, working environment and management. This has led to a severe lack of key skills, rising levels of career switching and early retirement, as well as national and international migration. In sub-Saharan Africa, where all the issues mentioned above are combined with the HIV/AIDS pandemic, there are an estimated 750 000 health workers in a region that is home to 682 million people. By comparison, the ratio is ten to 15 times higher in OECD countries, whose ageing population is putting a growing



WHO's Dr Tim Evans

strain on an over-stretched workforce.

Solutions to this crisis must be worked out at local, national and international levels, and must involve governments, the United Nations, health professionals, non-governmental organizations and community leaders.

There is no single solution to such a complex problem, but ways forward do exist and must now be implemented. For example, some developed countries have put policies in place to stop active recruitment of health workers from severely understaffed countries.

Some developing countries have revised their pay scales and introduced non-monetary incentives to retain their workforce and deploy them in rural areas. Education and training procedures have been tailored to countries' specific needs. Community health workers are helping their communities to prevent and treat key diseases. Action must be taken now for results to show in the coming years.

In 2006, World Health Day (celebrated annually on 7 April), will be devoted to the health workforce crisis. On this day around the globe, hundreds of organizations will host events to draw attention to the global health workforce crisis and celebrate the dignity and value of working for health. We invite you to join with WHO and other organizations to celebrate World Health Day 2006. Together, we can make a difference.

Assistant Director-General Evidence and Information for Policy, World Health Organisation

DRUG CHART

INFECTIOUS DISEASES INSTITUTE

THE UNIVERSITY of LIVERPOOL



Protease Inhibitor Drug Interactions (1)

	APV	ATV	Ν	LPV
Analgesics Alfentanyl	•			
Aspirin	•	-		- 🕌
Buprenorphine Dextropropoxyphene	•			
Diamorphine				
Fentanyl			•	
Ibuprofen Methadone	•	•	· •	•
Morphine				
Paracetamol Pathidina (Manaridina)	•	•	÷	•
Pethidine (Meperidine) Piroxicam				
Tramadol				
Antiarrhythmics Amiodarone		•		
Bepridil		•	Ū.	
Disopyramide				
Flecainide Lidocaine (Lignocaine)	•	•	•	•
Mexiletine				
Propafenone	•	•		
Quinidine Antibacterials		-	-	
Azithromycin	٠	•	٠	٠
Ciprofloxacin	* * * □ □ * * * 0 □ * * * * 0 □ * * * *	• • • • • • • • • • • • • • • • • • • •		• • • • • • • • • • • • • • • • • • • •
Clarithromycin Clindamycin		•		•
Dapsone		•	•	•
Erythromycin Ethambutol		•	•	
Isoniazid	÷	÷.	÷.	- -
Metronidazole	•		•	
Ofloxacin Pyrazinamide	1			:
Rifabutin	ò	Ū.	ò	- ò
Rifampicin	•	•	•	•
Rifapentine Streptomycin	•	•	•	•
Tetracyclines	•	•	•	•
Trimethoprim/Sulfamethoxazole	•	•	•	•
Anticonvulsants Carbamazepine	•			
Clonazepam	•			
Ethosuximide				
Gabapentin Lamotrigine	÷.	- -	•	•
Phenobarbital				
Phenytoin Valproate				
Vigabatrin	÷	•	<u> </u>	•
Antidepressants				
Amitriptyline Bupropion				
Citalopram				
Desipramine				
Doxepin Fluoxetine	8			8
Mirtazapine				
Nefazodone Nortriptyline				•
Paroxetine	ō		ō	
Sertraline				
Antifungals				
Amphotericin B Caspofungin	ŏ.	-	- -	- i
Fluconazole	•	•	•	•
Flucytosine Itraconazole	•	•	•	•
Ketoconazole	•			
Miconazole	0		•	
Terbinafine Voriconazole	•			
Antihistamines				-
Astemizole	•	•	•	•
Cetirizine Fexofenadine		•		•
Loratadine		ō		0
Terfenadine	•	•	•	٠
Antimigraines				
Ergotamine & Ergot derivatives Sumatriptan	•	•	•	•
Key to abbreviations				
APV Amprenavir/Fosamprenavir (Agenerase [®] , Telzir [®] , Lexiva [®])	LPV NFV	Lopina	vir (Kalet	tra [®])
(rigonordos , reizir , Eckiva)	INEV	INEITINE	avir (Virac	eh(_)

	APV	ATV	≧	LΡV
Antineoplastics		_	_	_
Cyclophosphamide				
Doxorubicin	÷	•	•	•
Paclitaxel Vinblastine	÷.	H	H	8
Vincristine	- E			- D
Antiplatelet and Anticoagula	ant			
Clopidogrel	•	•	•	•
Warfarin				
Antiprotozoals				
Atovaquone	•		•	
Chloroquine Halofantrine	1	•	•	•
Lumefantrine				
Mefloquine	÷.	- - -	- -	- 🖡
Pentamidine	•	•	•	•
Proguanil	•	•	•	•
Pyrimethamine	•	•	•	•
Antipsychotics/Neuroleptics				
Chlorpromazine	<u> </u>			
Clozapine				
Haloperidol Olanzapine	•			
Perphenazine	-	-	-	
Pimozide	•	•	•	•
Risperidone	٠	٠	٠	٠
Thioridazine	٠	٠	٠	٠
Antiretrovirals				
Fusion Inhibitor				
Enfuvirtide (T20)	•	•	•	•
NNRTIs Delavirdine				
Efavirenz	H			8
Nevirapine	ä	ä	ä	
Nucleoside/Nucleotide Analogues	-	-	-	
Abacavir	•	•	•	•
Didanosine (ddl)				
Emtricitabine (FTC)	•	•	•	•
Lamivudine (3TC)	•	•	•	•
Stavudine (d4T)	•	<u> </u>	•	<u> </u>
Tenofovir Zalcitabino (ddC)	1		1	
Zalcitabine (ddC) Zidovudine (AZT/ZDV)	1	1	1	- I
Protease Inhibitors				
Amprenavir			•	
Atazanavir			•	
Indinavir	•	•		
Lopinavir	•			
Nelfinavir Ritonavir		H	- H	8
Saquinavir	- H	- H	-	
Tipranavir			Ū.	
Antivirals				
Aciclovir	•	٠	٠	٠
Adefovir	٠	٠	٠	٠
Cidofovir	•	•	•	٠
Famciclovir	•	•	•	•
Foscarnet				
Ganciclovir Ribavirin	1			
Valaciclovir				
Anxiolytics/Hypnotics/Sedat	tives			·
Alprazolam			•	
Chlordiazepoxide	•	•	•	•
Clorazepate				
Diazepam	•			
Estazolam				
Flurazepam	•			
Lorazepam Midazolam				1
Oxazepam	-			-
Temazepam	•	•	•	•
Triazolam	•	•	•	•
Zolpidem				
Beta Blockers				
Atenolol	•		٠	
Bisoprolol	•		•	
Carvedilol				
Metoprolol				
Propranolol		1	-	
Propranolol Bronchodilator	•			

Key to symbols

•	These drugs should not be coadministered
	Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration
	No clinically significant interaction
0	There are no clear data, actual or theoretical, to indicate

	APV	ATV	D۷	LPV
Calcium Channel Antagoni	sts			_
Amlodipine				
Diltiazem				
Nicardipine				
Nifedipine Nisoldipine	- H		ä	8
Verapamil	- H	- H	- H	
Erectile Dysfunction Agent	•			
Apomorphine				
Sildenafil				
Tadalafil				
Vardenafil			•	
Gastrointestinal Agents	•	_		
Cimetidine Cisapride				
Domperidone		1	1	
Dronabinol	- č	ò	ò	- č
Famotidine				•
Lansoprazole			•	•
Loperamide	•		•	
Metoclopramide	.	•	.	<u> </u>
Omeprazole				
Ondansetron Prochlorperazine				
Ranitidine	- č	ò	÷	
General Anaesthetics				
Enflurane	•	•	•	•
Halothane	•	•	•	•
Ketamine	•	•	•	•
Herbals/Nutraceuticals	_	_	_	_
Echinacea	-			
Garlic Grapefruit juice		.	.	
Milk thistle	- i	- i	- i	•
Seville orange juice	-	-	-	
St John's Wort	•	•	•	:
Vitamin E	•	•	•	•
Illicit/Recreational				
Alcohol	<u>•</u>	<u>•</u>	<u>•</u>	<u> </u>
Gamma-hydroxybutyrate Marijuana	<u> </u>		.	
MDMA ("Ecstasy")			, i	8
Methamphetamine				
Immune Modulators				
Hydroxyurea	•	•	•	•
Interferon alpha	•	•	•	•
Interleukin 2 Peginterferon alfa-2a				1
Immunosuppressants	•	•	•	•
Ciclosporin				
Mycophenolate	-	-	-	•
Sirolimus	Ū.		Ū.	
Tacrolimus				
Lipid Lowering Agents				
Atorvastatin				
Clofibrate Fenofibrate				
Fluvastatin				
Gemfibrizil	•	•	•	
Lovastatin	•	•	•	•
Pravastatin	•	•	•	٠
Rosuvastatin	•	•	•	٠
Simvastatin	•	•	•	•
Simvastatin Oral Anti-diabetics	•	•	•	-
Simvastatin Oral Anti-diabetics Glipizide	•	•	•	
Simvastatin Oral Anti-diabetics Glipizide Metformin		•		-
Simvastatin Oral Anti-diabetics Glipizide Metformin Rosiglitazone	•	•	•	•
Simvastatin Oral Anti-diabetics Glipizide Metformin Rosiglitazone Tolbutamide	•	•	•	•
Simvastatin Oral Anti-diabetics Glipizide Metformin Rosiglitazone	•	•	•	•
Simvastatin Oral Anti-diabetics Glipizide Metformin Rosiglitazone Tolbutamide Steroids Dexamethasone Ethinylestradiol	•	•	•	•
Simvastatin Oral Anti-diabetics Gilpizide Metformin Rosiglitazone Tolbutamide Steroids Dexamethasone Ethinylestradiol Megestrol acetate	•	•	•	•
Simvastatin Oral Anti-diabetics Glipizide Metformin Rossigilitazone Tolbutamide Steroids Dexamethasone Ethinylestradiol Megestrol acetate Nandrolone	•	•	•	•
Simvastatin Oral Anti-diabetics Glipizide Metformin Rosiglitazone Tolbutamide Steroids Dexamethasone Ethinylestradiol Megestrol acetate Nandrolone Prednisolone	•	•	•	•
Simvastatin Oral Anti-diabetics Glipizide Metformin Rossigilitazone Tolbutamide Steroids Dexamethasone Ethinylestradiol Megestrol acetate Nandrolone	•	•	•	•

Charts revised February 2005

Full information available at www.hiv-druginteractions.org Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

© Liverpool HIV Pharmacology Group, University of Liverpool Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF

Although great care has been taken in compiling and checking that this information is accurate, the University of Liverpool, and its servants or agents shall not be responsible or in anyway liable for the continued currency of the information or for any errors, omissions or inaccuracies in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

IDV Indinavir (Crixivan®)

Atazanavir (Reyataz®)

ATV

RTV Ritonavir (Viracept SQV Saquinavir (Invirase[®], Fortovase



Protease Inhibitor Drug Interactions (2)

	NFV	RTV	sqv
Analgesics		_	
Alfentanyl			
Aspirin	•	•	÷
Buprenorphine	-		
Dextropropoxyphene			
Diamorphine Fentanyl	H	ä	
Ibuprofen	-		
Methadone	<u> </u>		•
Morphine			
Paracetamol	•	+	•
Pethidine (Meperidine)		•	
Piroxicam		•	
Tramadol Antiarrhythmics			<u> </u>
Amiodarone			
Bepridil	- ē	•	•
Disopyramide			
Flecainide		•	•
Lidocaine (Lignocaine)			
Mexiletine			
Propafenone			
Quinidine	-	-	_
Antibacterials Azithromycin		•	
Ciprofloxacin		-	
Clarithromycin	•	ė.	•
Clindamycin	•		
Dapsone	•	•	
Erythromycin	•		•
Ethambutol	•	• • • • • • • • • • • • • • • • • • • •	•
Isoniazid Metronidazole	. I.		
Ofloxacin	- I -	- -	- I.
Pyrazinamide	÷	÷ .	- -
Rifabutin			•
Rifampicin	•		•
Rifapentine			
Streptomycin	•	•	•
Tetracyclines Trimethoprim/Sulfamethoxazole			1
Anticonvulsants	-		
Carbamazepine			
Clonazepam			•
Ethosuximide			
Gabapentin	•	•	•
Lamotrigine			<u> </u>
Phenobarbital Phenytoin	- H		- H
Valproate		ä	- -
Vigabatrin	-	•	÷ .
Antidepressants			
Amitriptyline	•		
Bupropion			
Citalopram			
Desipramine	•		
Doxepin			
Fluoxetine Mirtazapine			
Nefazodone		ä	
Nortriptyline	•		
Paroxetine	•		
Sertraline			
Antifungals			
Amphotericin B	•	•	•
Caspofungin			•
Fluconazole Flucytosine	1		
Itraconazole		n in	, in
Ketoconazole	•	ö	-
Miconazole	ò		•
Terbinafine	•	•	•
Voriconazole		•	
Antihistamines			
Astemizole	•	•	•
Cetirizine		•	.
Fexofenadine Loratadine			H
Terfenadine			
Antimigraines		-	
Ergotamine & Ergot derivatives			
Sumatriptan	•	•	•
Key to abbreviations			

 Amprenavir/Fosamprenavir (Agenerase[®], Telzir[®], Lexiva[®])
 LPV
 Lopinavir (Kaletra[®])

 NFV
 Nelfinavir (Viracept[®])

SQV

RTV Ritonavir (Norvir®)

Saquinavir (Invirase[®], Fortovase[®])

	NFV	RTV	sqv
Antineoplastics	z	R	Ő.
Cyclophosphamide			
Doxorubicin	÷	•	•
Paclitaxel Vinblastine			8
Vincristine	ä	ä	ä
Anti-platelet and Anti-coag	ulant		
Clopidogrel	<u>•</u>	•	•
Warfarin			
Antiprotozoals Atovaquone	•	•	•
Chloroquine	•		•
Halofantrine Lumefantrine	•	•	•
Mefloquine		- -	- -
Pentamidine	•	i i	•
Proguanil	•		•
Pyrimethamine Antipsychotics/Neuroleptic	•		•
Chlorpromazine			•
Clozapine	•		•
Haloperidol	<u>+</u>		<u>+</u>
Olanzapine Perphenazine		8	
Pimozide	•	•	•
Risperidone	•		•
Thioridazine	•		•
Antiretrovirals Fusion Inhibitors			
Enfuvirtide (T20)	•	•	•
NNRTIS	_	_	_
Delavirdine Efavirenz			
Nevirapine	ö		ö
Nucleoside/Nucleotide Analogues			
Abacavir Didee esine (ddl)	<u>+</u>	<u>+</u>	<u> </u>
Didanosine (ddl) Emtricitabine		.	.
Lamivudine (3TC)	•	•	•
Stavudine (d4T)	•	<u>+</u>	•
Tenofovir Zalcitabine (ddC)		4	
Zidovudine (AZT/ZDV)	÷	÷ .	÷ .
Protease Inhibitors		_	_
Amprenavir Atazanavir			- H
Indinavir			
Lopinavir			
Nelfinavir Ritonavir			
Saquinavir			
Tipranavir			
Antivirals			
Aciclovir Adefovir	1	- 1 -	•
Cidofovir	÷	÷ .	
Famciclovir	•	•	•
Foscarnet Ganciclovir			
Ribavirin			
Valaciclovir	•	•	•
Anxiolytics/Hypnotics/Seda	atives	_	_
Alprazolam			
Chlordiazepoxide Clorazepate			
Diazepam	- E	•	
Estazolam		•	
Flurazepam	•		•
Midazolam	•	•	•
Oxazepam	•	•	•
Temazepam Triazolam			:
Zolpidem		•	
Beta Blockers			
Atenolol	•		•
Bisoprolol Carvedilol			
Metoprolol	-	ä	-
Propranolol	•		•
Bronchodilators		_	
Theophylline	•	0	•

Key to symbols

•	These drugs should not be coadministered
	Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration
	No clinically significant interaction
0	There are no clear data, actual or theoretical, to indicate

	NFV	RTV	sqv
Calcium Channel Antagoni	sts	-	
Amlodipine Diltiazem			
Nicardipine		ä	
Nifedipine	ö	ä	ä
Nisoldipine		-	
Verapamil			
Erectile Dysfunction Agent			
Apomorphine			
Sildenafil			
Tadalafil Vardenafil			8
Gastrointestinal Agents	-	-	
Cimetidine	•	•	•
Cisapride	•	•	•
Domperidone	•	•	•
Dronabinol			
Famotidine	•	•	•
Lansoprazole	•		<u>•</u>
Loperamide	•		
Metoclopramide Omeprazole			•
Ondansetron			
Prochlorperazine	•		•
Ranitidine	•	•	•
General Anaesthetics			
Enflurane	•	•	•
Halothane	•	•	•
Ketamine	•	•	•
Herbals/Nutraceuticals	_	-	_
Echinacea		<u> </u>	
Garlic Grapefruit juice			
Grapefruit juice Milk thistle			
Seville orange juice	-	-	•
St John's Wort	•	•	•
Vitamin E	•	•	•
Illicit/Recreational			
Alcohol	•	•	•
Gamma-hydroxybutyrate			
Marijuana	<u>+</u>		
MDMA ("Ecstasy") Methamphetamine			
Methamphetamine Immune Modulators	-	-	-
Hydroxyurea	•		
Interferon alpha	•	•	•
Interleukin 2	•	•	•
Peginterferon alfa-2a	٠	•	٠
Immunosuppressants			
Ciclosporin			
Mycophenolate	•	•	•
Sirolimus			
Tacrolimus		٥	
Lipid Lowering Agents			-
Atorvastatin Clofibrate			
Fenofibrate			
Fluvastatin			
Gemfibrizil	•	•	•
Lovastatin	•	•	•
Pravastatin	•	•	•
Rosuvastatin	•	•	•
Simvastatin	•	•	•
Oral Anti-diabetics	_	_	_
Glipizide			
Metformin			•
Rosiglitazone Tolbutamide			, in the second
Steroids	-	-	-
Dexamethasone		D.	
Ethinylestradiol			
Megestrol acetate	•		•
Nandrolone	•	•	•
Prednisolone			
Progesterone/Progestogen			
Stanazolol Testosterone	U	-	

THE UNIVERSITY of LIVERPOOL

INFECTIOUS DISEASES INSTITUTE

Full information available at www.hiv-druginteractions.org Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

© Liverpool HIV Pharmacology Group, University of Liverpool amacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF Ph

Although great care has been taken in compiling and checking that this information is accurate, the University of Liverpool, and its servants or agents shall not be responsible or in anyway liable for the continued currency of the information or for any errors, omissions or inaccuracies in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

ATIC News, January 2006

APV

ΑΤΥ

IDV Indinavir (Crixivan®)

Atazanavir (Reyataz®)

DRUG CHART

h

INFECTIOUS DISEASES

THE UNIVERSITY



NNRTI Drug Interactions

	DLV	EFV	NVP
Analgesics			
Alfentanyl Aspirin			
Buprenorphine		- <u>-</u>	- <u>-</u>
Dextropropoxyphene		•	•
Diamorphine	•	•	•
Fentanyl			
Ibuprofen Methadone		- 🔒 -	· 👬
Morphine	- - -	- 👗 - I	- 👗
Paracetamol	•	•	•
Pethidine (Meperidine)		•	•
Piroxicam	• <u>•</u>	· 📩	•
Tramadol Antiarrhythmics	<u> </u>	<u> </u>	•
Amiodarone			
Bepridil		•	
Disopyramide			
Flecainide			
Lidocaine (Lignocaine) Mexiletine	- H	- H	8
Propafenone	- H	- <u> </u>	- H
Quinidine			
Antibacterials			
Azithromycin	+	•	•
Ciprofloxacin	<u>•</u>	. 👲 .	· 👲
Clarithromycin Clindamycin			
Dapsone	- i		- -
Erythromycin	•	•	•
Ethambutol	+	•	•
Isoniazid	•	•	•
Metronidazole Ofloxacin			
Pyrazinamide	÷ .	- 👗 · ·	÷ ∔
Rifabutin			
Rifampicin	•		
Rifapentine			
Streptomycin Tetracyclines	. I.	- 1	- I.
Trimethoprim/Sulfamethoxazole	÷ .	- 🗼 · ·	÷ 🗼
Anticonvulsants			
Carbamazepine			
Clonazepam			
Ethosuximide Gabapentin	- -	- 🕌 -	· 🕌
Lamotrigine	÷ .	÷	- -
Phenobarbital			
Phenytoin			
Valproate	•	-	
Vigabatrin Antidepressants	•	•	•
Amitriptyline	•	•	•
Bupropion	i i	<u> </u>	•
Citalopram			
Desipramine	<u>•</u>	•	•
Doxepin Fluoxetine		- 1	· 1
Mirtazapine		- <u>.</u>	- <u>.</u>
Nefazodone			
Nortriptyline	•	•	•
Paroxetine	<u>+</u>	<u>•</u>	•
Sertraline	<u> </u>	<u> </u>	<u> </u>
Antifungals Amphotericin B		-	
Caspofungin		Ū.	Ū.
Fluconazole	•	•	
Flucytosine	•	•	•
Itraconazole			
Ketoconazole Miconazole			
Terbinafine	•	•	•
Voriconazole		•	
Antihistamines			
Astemizole	•	•	
Cetirizine	.	•	.
Fexofenadine Loratadine			•
Terfenadine	•	•	
Antimigraines			
Ergotamine & Ergot derivatives	•	•	•
Sumatriptan	٠	•	٠
			_

Antineoplastics Cyclophosphamide Doxorubicin Pacilitaxel Vinolastine Vinoristine Anti-coagulant Clopidogrel Wafarin Antiprotozoals Atovaquone Chloroquine Halofantrine Lumefantrine Halofantrine Proquani Proquani Proquani Proquani Proquani Proquani Propuani Propuani Propuani Propuani Propuani Propuani Perphenazine Perphenazine Perphenazine Perphenazine Perphenazine Perphenazine Perphenazine Perphenazine Cloiazapine Perphenazine Perp) L	EFV	٩V
Cyclophosphamide Image: Cyclophosphamide Image: Cyclophosphamide Paclitaxel Image: Cyclophosphamide Image: Cyclophosphamide Paclitaxel Image: Cyclophosphamide Image: Cyclophosphamide Vincristine Image: Cyclophosphamide Image: Cyclophosphamide Anti-platelet and Anti-coagulant Image: Cyclophosphamide Image: Cyclophosphamide Antiser: Cyclophosphamide Image: Cyclophosphamide Image: Cyclophosphamide Pyrimethamine Image: Cyclophosphamide Image: Cyclophosphamide Propenazine Image: Cyclophosphamide Image: Cyclophosphamide Phimozide Image: Cyclophosp	Antineoplastics	-	ш	Z
Doxorubicin • • Paciltaxel □ □ Vinoliastine □ □ Anti-platelet and Anti-coagulant • • Clojdogrel • • Warfarin □ □ Anti-platelet and Anti-coagulant • • Clojdogrel • • Warfarin □ □ Anti-platelet and Anti-coagulant • • Choroquine • • • Halofantrine □ □ □ Lumefantrine □ □ □ Proguani • • • Pyrimethamine • • • Anti-plateits/Neuroleptics □ □ □ Choromazine • • • Parbinazine □ □ □ Parbenazine □ □ □ Parbenazine □ □ □ NNRTis □ □ □ □ Delavirdine □ □ □ <td></td> <td></td> <td></td> <td></td>				
Vincistine Image: Constraint of the second seco	Doxorubicin	•	•	•
Vincristine Image: Construct of the second sec				
Anti-platelet and Anti-coagulant Clopidogrel Choroquine Chorophone Cho				
Clopidogrel Warfarin Antiprotozoals Atavaquone Chloroquine Halofantine Lumefantrine Mefloquine Pentamidine Proguanil Pyrimethamine Antipsychotics/Neuroleptics Chloropromazine Clozapine Haloperidol Olanzapine Haloperidol Olanzapine Parphenazine Pimozide Risperidone Clozapine Haloperidol Olanzapine Parphenazine Pimozide Clozapine Haloperidol Olanzapine Parphenazine Pimozide Clozapine Antiretrovirals Fusion Inhibitors Enfuvitide NUNRTis Delavidine Etavienz Abacavir Didanosine (ddl) Entricitabine Lamivudine (3TC) Stavudine (AZT/ZDV) Protease Inhibitors Angrenavir Lopinavir Clozivir Antizzanavir Clozivir Antazanavir Clozivir Antorice/Clozivir Antor		ulant		
Antiprotozoals Atovaquone Atovaquone Chicroquine Halofantrine Uumefantrine Mefloquine Pentamine Proguani Pyrimethamine Antipsychotics/Neuroleptics Choropromazine Clozapine Haloperidol Olanzapine Perphenazine Pimozide Risperidone Thioridazine Antiertovirals Fusion Inhibitors Enfuvirtide NVR7Is Delavirdine Efavirenz Abacavir Didanosine (dd1) Entricitabine Lamivudine (3TC) Stavudine (42T)/ZDV) Protease Inhibitors Atazanavir Indinavir Doginari Atazanavir Indinavir Choroprovi Saquinavir Choroprovi Atazanavir Indinavir Choroprovi Choroprovi Atazanavir Choroprovi Choroprov		•	•	•
Ativaquone Chloroquine Halofantrine Lumefantrine Halofantrine Proguani Pyrimethamine Antipsychotics/Neuroleptics Chlorpromazine Clozapine Haloperidol Olanzapine Parphenazine Pimozide Clozapine Halofantrine Pimozide Clozapine Parphenazine Perphenazine Pimozide Clozapine Parphenazine Pimozide Clozapine Parphenazine Pimozide Clozapine Parphenazine Pimozide Clozapine Clozapan Clozapine Clozapan Cloza	Warfarin			
Chloroquine Halofantrine Lumefantrine Proquanil Proguanil Proscontil Proscontil Proscontil Proguanil Proguanil Proguanil Proguanil Proguanil Proguanili Propranoli Propranoli				
Halofantine Lumefantrine Halogrintine Proguani Pyrimethamine Antipsychotics/Neuroleptics Chlorpromazine Clozapine Halogridol Olanzapine Parphenazine Pimozide Risperidon Olanzapine Parphenazine Pimozide Risperidon Olanzapine Parphenazine Pimozide Antiretrovirals Fusion Inhibitors Enfuvirtide Antiretrovirals Abacavir Didanosine (ddl) Entricitabine Lamivudine (3TC) Stavudine (42T) Tenofovir Zalcitabine (ddC) Zidovudine (AZT/ZDV) Protease Inhibitors Amprenavir Clozapine Abacavir Didanosine (ddl) Compensite Clozitabine (ACT/ZDV) Atazanavir Clozitabine (ACT/ZDV		- •	- •	•
Lumefantrine Image: Second Secon		· ·	· .	- -
Pentamidine Proguani Proguani Proguani Proguani Promozine Clozapine Haloperidol Olanzapine Perphenazine Perph		•		
Proguanil • • Pyrimethamine • • Antipsychotics/Neuroleptics • • Chlorpromazine • • • Clazapine • • • • Perphenazine • • • • • Perphenazine • • • • • • Perphenazine • <		•	•	•
Pyrimethamine Antipsychotics/Neuroleptics Chlorpromazine Clozapine Haloperidol Olanzapine Perphenizine Perphenizine Primoridazine Antiretrovirals Fusion Inhibitors Enfuvitide ANTIs Delavirdine Efavirenz Abacavir Didanosine (ddl) Entricitabine Lamivudine (3TC) Stavudine (AZTZDV) Zidovudine (AZTZDV) Zidovudine (AZTZDV) Zidovudine (AZTZDV) Atazanavir Didanosine Clozapine Aciclovir Abacavir Clozapine Aciclovir Abacavir Clozapine Aciclovir Abacavir Clozapine Clozapam Clozapine Clozapam Clozapine Clozapam Clozapine Clozapam Clozapine Clozapam Clozapine Clozapam Clozapam Clozapam Clozapam Clozapam Clozapam Clozapam Clozapine Clozapam Clo		- • •		•
Antipsychotics/Neuroleptics Chicorpromazine Haloperidol Olanzapine Perphenazine Pimozide Risperidone Thioridazine Antiretrovirals Fusion Inhibitors Enfuvirtide WNR7Is Delavirdine Efavirenz Nevirapine Nucleoside/Nucleotide Analogues Abacavir Didanosine (ddl) Etavirenz Nationavir Didanosine (ddT) Stavudine (d4T) Tenofovir Zalottabine (d2T/ZDV) Protease Inhibitors Amprenavir Indinavir Cidotovir Atazanavir Indinavir Cidotovir Saquinavir Saquinavir Cidotovir Adefovir Cidotovir Adefovir Cidotovir Adefovir Cidotovir Antivirals Acicolavir Antiorizs/Staputa Acicolavir Antiorizs/Approtics/Sedatives Appravin Valaciclovir Amprenavir Cidotovir Adefovir Cidotovir Adefovir Cidotovir Adefovir Cidotovir Adefovir Cidotovir Antiorizs/Approtics/Sedatives Appravin Valaciclovir Appravin Cidotovir Amprenavi Cidotovir Amprenavi Cidotovir Amprenavi Cidotovir Amprenavi Cidotovir Amprenavi Cidotovir Amprenavi Cidotovir Amprenavi Cidotovir Antiorizs/Approtics/Sedatives Amprenavi Cidotovir Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi Amprenavi A			- 1 -	
Chiorpromazine Clozapine Haloperidol Olanzapine Haloperidol Olanzapine Pimozide Pimozide Risperidone Thioridazine Antiretrovirals Fusion Inhibitors Enfuvirtide NVR7Is Delavirdine Efavirenz Nveriapine Nucleoside/Nucleotide Analogues Abacavir Didanosine (dd1) Charosine (d		15	•	•
Clozapine Haloperidol Olanzapine Haloperidol Olanzapine Perphenazine Perpenale Per			•	•
Olarzapine Image: I		•	•	•
Perphenazine Pimozide Risperidone Thiordazine Risperidone Thiordazine Risperidone Thiordazine Risperidone Thiordazine Risperidone Thiordazine Ruschark Rusch		<u>+</u>	<u>+</u>	<u>+</u>
Pimozide Risperidone Thioridazine Antiretrovirals Fusion Inhibitors Enfuvirtide NINRTIs Delavirdine Efavirenz Nucleoside/Nucleotide Analogues Abacavir Didanosine (ddl) Entricitabine Abacavir Didanosine (ddl) Entricitabine Abacavir Didanosine (ddl) Entricitabine Abacavir Didanosine (ddl) Entricitabine Abacavir Didanosine (ddl) Composition Co		- 💾 -	- <mark>-</mark> -	- <mark>-</mark>
Risperidone • • • • • • • • • • • • • • • • • • •		- č	•	- č
Antiretrovirals Fusion Inhibitors Enfuviritie WNRTIs Delavirdine Efavirenz Nevirapine Nucleoside/Nucleotide Analogues Abacavir Didanosine (ddl) Entricitabine Lamivudine (3TC) Stavudine (4TT) Tenofovir Zalcitabine (ddC) Zidovudine (AZT/ZDV) Protease Inhibitors Amprenavir Indinavir Lopinavir Clopinavir Clopinavir Clopinavir Clopovir Saquinavir Clodofovir Foscarnet Ganciclovir Ribavini Clodofovir Foscarnet Ganciclovir Ribavini Adefovir Clodofovir Foscarnet Ganciclovir Ribavini Clodofovir Foscarnet Clorazepate Clorazepate Clorazepate Clorazepat Cl		•	•	•
Fusion Inhibitors Entivirtide Image: Structure in the image: Stru		•	•	•
Enfuviride NWRTIs NNRTIs Delavirdine Efavirenz Nucleoside/Nucleotide Analogues Abacavir Didanosine (ddl) Conside/Nucleotide Analogues Abacavir Didanosine (ddl) Conside/Nucleotide Analogues Abacavir Didanosine (dd1) Conside/Nucleotide Analogues Abacavir Didanosine (dd1) Conside/Nucleotide Analogues Abacavir Didanosine (dd1) Conside/Nucleotide Analogues Abacavir Conside/Nucleotide Analogues Aprenavir Conside/Nucleotide Analogues Atenolol Bisoprolol Carvedilol Carvedilol Metoprolol Conside/Nucleotide Bisonchorts Etacolcavir				
NNRTIs Delavirine Efavirenz Nevirapine Nucleoside/Nucleotide Analogues Abacavir Didanosine (ddl) Emtricitabine Lamivudine (3TC) Stavudine (d4T) Zalcitabine (ddC) Zidovudine (AZT/ZDV) Protease Inhibitors Amprenavir Lopinavir Lopinavir Lopinavir Saquinavir Indinavir Indinavir Saquinavir				
Delavirdine Image: Constraint of the second sec		· · · · ·		•
Nevirapine Image: Constraint of the second of the seco				
Nucleoside/Nucleotide Analogues Abacavir Didanosine (ddl) Emtinicitabine Lamivudine (3TC) Stavudine (d4T) Tenofovir Zalcitabine (d4C) Amprenavir Lopinavir Lopinavir Saquinavir Tipranavir Saquinavir Tipranavir Saquinavir Tipranavir Aciclovir Aciclovir Adefovir Cidofovir Famciclovir Famciclovir Valaciclovir Alprazolam Chiordiazepoxide Chiordiazepoxide Chiordiazepoxide Chiordiazepoxide Chiordiazepoxide Chiordiazepoxide Chiordiazepoxide Chiordiazepoxide Chiordiazepoxide Chiordiazepoxi				
Abacavir Didanosine (ddl) Emtricitabine Canada and and and and and and and and an				
Didanosine (dd1) Emtricitabine Lamivudine (3TC) Stavudine (d4T) Tenofovir Zalcitabine (ddC) Zidovufine (AZT/ZDV) Protease Inhibitors Amprenavir Lopinavir Lopinavir Ritonavir Saquinavir Ritonavir Saquinavir Correction Antivirals Aciclovir Activirals Aciclovir Antivirals Aciclovir Bisochem Clorazepate		s _		
Emticitabine Lamivudine (3TC) Stavudine (3TC) Zidovudine (AZT/ZDV) Protease Inhibitors Amprenavir Protease Inhibitors Amprenavir Atazanavir Atazanavir I I Indinavir I I I Indinavir I I I I I I I I I I I I I I I I I I I		- i	· 🗼 · ·	÷ .
Stavudine (d4T) • Tenofovir • Zalcitabine (d4C) • Zldovudine (AZT/ZDV) • Protease Inhibitors • Amprenavir • Indinavir • Lopinavir • Statzanavir • Indinavir • Saquinavir • Tipranavir • Statinavir • Tipranavir • Aciclovir • Acidovir • Acidovir • Adeforir • Cidofovir • Famciclovir • Ribavrin • Valaciclovir • Alprazolam • Cliorazepate • Diazepam • Estazolam • Oxazepam • Trinzolam • Zolpidem • Bisoprolol • Propranolol •		•	•	•
Tenofovir • • Zalcitabine (ddC) • • Zidovudine (AZT/ZDV) • • Protease Inhibitors - - Amprenavir - - - Atazanavir - - - Indinavir - - - Lopinavir - - - Ritonavir - - - Saquinavir - - - Tipranavir - - - Actofovir - - - Cidofovir - - - Famciclovir - - - Foscarnet - - - Ganciclovir - - - Ribavirin - - - - Valaciclovir - - - - Anxiolytics/Hypnotics/Sedatives - - - Alprazolam - - - - Diazepam - - -		•	•	•
Zalcitabine (ddC) • • Zidovudine (AZT/ZDV) • • Protease Inhibitors • • Angrenavir • • Lopinavir • • • Lopinavir • • • Nelfinavir • • • • Ritonavir • • • • Saquinavir • • • • Tipranavir • • • • Aciclovir • • • • Aciclovir • • • • Adeforir • • • • Ganciclovir • • • • Famciclovir • • • • Foscarmet • • • • • Ganciclovir • • • • • • Valaciclovir • • • • • • • • • •		•	•	•
Zidovudine (AZT/ZDV) Protease Inhibitors		- I -	- I	- I.
Amprenavir Image: Constraint of the second of the seco		i 🗼 i	· 🗼 · ·	÷ 🗼
Atazanavir Image: Constraint of the second of the seco				
Indinavir Image: Im				
Lopinavir □ □ Nelfinavir □ □ Ritonavir □ □ Saquinavir □ □ Antivirals □ □ Adefovir □ □ Cidofovir □ □ Cidofovir □ □ Famciclovir □ □ Foscamet ○ □ Ganciclovir □ □ Ribavirin ○ □ Valaciclovir ○ □ Aprazolam □ □ Chlordiazepoxide ○ □ Clorazepate □ □ Diazepam □ □ Lorazepam □ □ Midazolam □ □ Oxazepam □ □ Triazolam □ □ Zoljdem □ □ Bisoprolol ○ ○ Bisoprolol □ □ Bisoprolol ○ ○ Propranolol ● ○ <td></td> <td></td> <td></td> <td>- H</td>				- H
Nefinavir □ □ Ritonavir □ □ Tipranavir □ □ Antivirals □ □ Aciclovir ▲ ▲ Adefovir □ ▲ Cidofovir ▲ ▲ Famciclovir ▲ ▲ Foscarnet ▲ ▲ Ganciclovir ▲ ▲ Valaciclovir ▲ ▲ Valaciclovir ▲ ▲ Alprazolam □ □ Chordiazepoxide ▲ ▲ Clorazepate □ □ Diazepam □ □ Flurazepam □ □ Lorazepam □ □ Chazepam □ □ Midazolam □ □ Oxazepam □ □ Triazolam □ □ Zolpidem □ □ Bisoprolol ▲ ▲ Propranolol ▲ ▲ Propranolol ▲ <				
Saquinavir Tipranavir Tipranavir Tipranavir Tipranavir Tipranavir Tipranavir Aciclovir Adefovir Cidofovir Famiciclovir Famiciclovir Famiciclovir Famiciclovir Anxiolytics/Hypnotics/Sedatives Anxiolytics/Hypnotics/Sedatives Anxiolytics/Hypnotics/Sedatives Anxiolytics/Hypnotics/Sedatives Clorazepate Chorazepate Chorazep				
Tipranavir Image: Constraint of the second sec				•
Antivirals Aciclovir Adefovir Cidofovir Famciclovir Fanciclovir Foscarnet Ganciclovir Ribavirin Valaciclovir Alprazolam Chlordiazepoxide Clorazepate Diazepam Estazolam Clorazepate Diazepam Diazepam Charden Stazolam Charden Charden Charden Beta Blockers Atenolol Bisoprolol Bisoprolol Bisoprolol Bisoprolol Bisoprolol Bisoprolol Bisoprolol Bisoprolol Atenolol Bisoprolol Bisoprolol Atenolol Atenolol Bisoprolol Carvedilol Bisoprolol Fornchodilators				
Aciclovir Adefovir Cidofovir Famicilovir Famicilovir Famicilovir Famicilovir Famicilovir Foscarnet Ganciclovir Valaciclovir Valaciclovir Valaciclovir Valaciclovir Valaciclovir Valaciclovir Citorazepam Citordiazepoxide Ciorazepate Citorazepate Citorazep				
Adefovir Cidofovir Famciclovir Foscarnet Ganciclovir Ribavrin Valaciclovir Axiolytics/Hypnotics/Sedatives Aprazolam Chlordiazepoxide Clorazepate Diazepam Estazolam Flurazepam Midazolam Oxazepam Triazolam Zolpidem Beta Blockers Atenolol Bisoprolol Propranolol		•	•	•
Fanciclovir • Foscarnet • Ganciclovir • Ribavirin • Valaciclovir • Anxiolytics/Hypnotics/Sedatives • Alprazolam • Chordiazepoxide • Ciorazepate • Diazepam • Lorazepam • Corazepam • Oxazepam • Temazepam • Triazolam • Zolpidem • Bisoprolol • Atenolol <td></td> <td>Ū.</td> <td>•</td> <td>•</td>		Ū.	•	•
Foscarnet • • Ganciclovir • • Ribavirin • • Valaciclovir • • Anxiolytics/Hypnotics/Sedatives • • Alprazolam • • Chordiazepoxide • • Clorazepate • • Diazepam • • Flurazepam • • Chazepam • • Midazolam • • Oxazepam • • Temazepam • • Tamazepam • • Triazolam • • Zolpidem • • Bisoprolol • • Propranolol • • Metoprolol • • Propranolol • •		•	•	•
Ganciclovir Ganciclovir Valaciclovir Valacic		•		•
Ribavrin • • Valaciclovir • • Alprazolam • • Alprazolam • • Chlordiazepoxide • • Clorazepate • • Diazepam • • Estazolam • • Flurazepam • • Midazolam • • Oxazepam • • Triazolam • • Zolpidem • • Bisoprolol • • Carvedilol • • Metoprolol • • Bronchodilators • •				
Valaciclovir Anxiolytics/Hypnotics/Sedatives Alprazolam Chlordiazepoxide Chorzepate Diazepam Diazepam Estazolam Chorzepate Chorzepat		•	•	•
Alprazolam Chlordiazepoxide Chlordiazepoxide Chlordiazepoxide Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate Chlordiazepate <li< td=""><td></td><td>•</td><td>•</td><td>٠</td></li<>		•	•	٠
Chiordiazepoxide Chiordiazepoxide Chiorazepam Chiorazepam		atives		
Clorazepate Image: Clorazepate Diazepam Image: Clorazepam Estazolam Image: Clorazepam Flurazepam Image: Clorazepam Midazolam Image: Clorazepam Oxazepam Image: Clorazepam Tritazolam Image: Clorazepam Tritazolam Image: Clorazepam Zolpidem Image: Clorazepam Beta Blockers Image: Clorazepailol Atenolol Image: Clorazepailol Bisoprolol Image: Clorazepailol Propranolol Image: Clorazepailol Bronchodilators Image: Clorazepailol		•		
Diazepam □ □ Estazolam □ □ Flurazepam □ □ Lorazepam • • Midazolam • □ Oxazepam • • Temazepam • • Tamazepam • • Colgodem □ □ Bisoprolol • • Carvedilol □ □ Metoprolol • • Propranolol • • Bronchodilators • •				
Estazolam I I Flurazepam I I Lorazepam I I Midazolam I I Oxazepam I I Temazepam I I Triazolam I I Zolpidem I I Beta Blockers I I Atenolol I I Bisoprolol I I Carvedilol I I Metoprolol I I Bronchodilators I I			ā	
Lorazepam Midazolam Oxazepam Temazepam Tiniazolam Zolpidem Beta Blockers Atenolol Bisoprolol Carvedilol Metoprolol Propranolol Bronchodilators	Estazolam			
Midazolam • • Oxazepam • • Temazepam • • Triazolam • • Zolpidem • • Beta Blockers • • Atenolol • • Bisoprolol • • Carvedilol • • Propranolol • • Bronchodilators • •				
Oxazepam		•	•	•
Temazepam Triazolam Zolpidem Beta Blockers Atenolol Bisoprolol Carvedilol Propranolol Bronchodilators		-		-
Triazolam • • Zolpidem • • Beta Blockers • • Atenolol • • Bisoprolol • • Carvedilol • • Metoprolol • • Propranolol • • Bronchodilators • •		•	•	•
Beta Blockers Atenolol Bisoprolol Carvedilol Metoprolol Propranolol Bronchodilators	Triazolam	•	•	
Atenolol Bisoprolol Carvedilol Propranolol Propranolol Bronchodilators				
Propranolol Pronchodilators				
Propranolol Pronchodilators				
Propranolol Pronchodilators		, in the second	, in the second	
Propranolol Pronchodilators		•	•	•
		+	•	•
Theophylline 🔶 🔶 🔶				

Key to symbols

•	These drugs should not be coadministered
	Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration
•	No clinically significant interaction

Calcium Channel Antagonists Amlodipine Image: Calcium Channel Antagonists Amlodipine Image: Calcium Channel Antagonists Amlodipine Image: Calcium Channel Antagonists Nicardipine Image: Calcium Channel Antagonists Nicardipine Image: Calcium Channel Antagonists Nicardipine Image: Calcium Channel Antagonists Apomorphine Image: Calcium Channel Antagonists Cimetidine Image: Calcium Channel Antagonists Cimetidine Image: Calcium Channel Antagonists Condansetron Image: Calcium Channel Antagonists Pranotidine Image: Calcium Channel Antagonists Calcium Channel Image: Calcium Channel Halothane Image: Calcium Channel Katamine Image: Calcium Channel Halothane Image: Calcium Channel Katamine Image: Calcium Channel Halothane Image: Calcium Channel Katamine <				
Calcium Channel Antagonists		ILV	ΕV	IVP
Amiodipine Ditiazem Nicardipine Nicardipine Nicardipine Nicardipine Nicardipine Ditiazem	Calcium Channel Antagoni			2
Nisoldipine				
Nisodipine □ □ □ Verapamil □ □ □ Erectile Dysfunction Agents □ □ □ Apomorphine □ □ □ □ Sidenafil □ □ □ □ □ Tadalafil □ □ □ □ □ □ Cimetidine □ <td></td> <td></td> <td></td> <td></td>				
Nisoldipine Image: constraint of the second s				
Verapamil □ □ Erectile Dysfunction Agents □ □ Apomorphine □ □ □ Sidlenafil □ □ □ □ Tadalafil □ □ □ □ □ Cimetidine □ □ □ □ □ □ Domperidone □ <td></td> <td></td> <td></td> <td></td>				
Erectile Dysfunction Agents Apomorphine Sildenafil Tadalafil Carbontestinal Agents Cimetidine Cisapride Domperidone Dronabinol Famotidine Lansoprazole Loperamide Omeprazole Omeprazole Ondansetron Prochlorperazine Ranitidine Enflurane Halothane Ketamine Halothane Ketamine Illicit/Recreational Alcohol Gamma-hydroxybutyrate Marijuana MDMA ("Ecstasy") Interferon alpha			ä	
Apomorphine		S		
Tadalafil	Apomorphine			
Vardenafil □ □ Gastrointestinal Agents □ □ Cimetidine □ □ □ Domperidone □ □ □ Dronabinol □ □ □ Famotidine □ □ □ Lansoprazole □ □ □ Loperanide ● ● ● Metoclopranide ● ● ● Ondansetron ● ● ● Prochioperazine ● ● ● Ranitidine □ □ □ ● General Anaesthetics □ □ □ □ Echinacea □ □ □ □ □ Gartic □				
Gastrointestinal Agents Cisapride Domperidone Dronabinol Famotidine Lansoprazole Loperamide Omeprazole Comeprazole Omeprazole Omeprazole Omeprazole Omeprazole Omeprazole Ondansetron Prochlorperazine Ranitidine General Anaesthetics Enflurane Halothane Ketamine Herbals/Nutraceuticals Echinacea Gartic Gartic Grapefruit juice Milk thistle Seville orange juice St John's Wort Vitamine Illicit/Recreational Alcohol Gamma-hydroxybutyrate Marijuana MDMA ("Ecstasy") Interleukin 2 Peginterferon alha-2a Interleukin 2 Peginterferon alha-2a Interleukin 2 Peginterferon alha-2a Interleukin 2 Echlo		- H	- H	- H
Cimetidine Cisapride Domperidone Domperidone Domparidone Dronabinol Famotidine Lansoprazole Loperamide Metoclopramide Omerprazole Ondansetron Prochlorperazine Ranitidine General Anaesthetics Enflurane Halothane Ketamine Halothane Ketamine Halothane Ketamine Cisapriti juice Miki thistle Seville orange juice St John's Wort Vitamin E Illicit/Recreational Alcohol Gamma-hydroxybutyrate Marijuana MDMA ("Ecstasy") Methamphetamine Hero alfa-2a Interferon alfa-2a Interfero			-	
Domperidone Dronabinol Famotidine Lansoprazole Loperamide Metoclopramide Omeprazole Ondansetron Prochlorperazine Rantidine General Anaesthetics Enflurane Halothane Katamine Halothane Katamine Herbals/Nutraceuticals Echinacea Garic Grapefriti juice Mik thistie Sevile orange juice St John's Wort Vitamin E Milcit/Recreational Alcohol Gamma-hydroxybutyrate Marijuana MDMA ("Estasy") Methamphetamine Methamphetamine Minterfev alfa-2a Minterfev al				•
Dronabinol □ □ Famotidine □ □ Lansoprazole □ □ Loperamide ● ● Metoclopraide ● ● Omenprazole ● ● Ondansetron ● ● Prochlorperazine ● ● Ranitdine ● ● General Anaesthetics □ □ Enflurane ● ● Halothane ● ● Ketamine □ □ Echinacea □ □ Garalic □ □ Grapefruit juice ● ● St John's Wort ● ● Vitamin E ■ ● Illicit/Recreational Alcohol ● Garmma-hydroxybutyrate ● ● Mathamphetamine ■ ● Interferon alfa-2a ● ● Immunosuppressants □ □ Ciclosporin □ □ □ Mycophenolate <td< td=""><td></td><td>•</td><td>•</td><td></td></td<>		•	•	
Famotidine • • Lansoprazole • • Loperamide • • Metoclopramide • • Omeprazole • • Ondansetron • • Prochlorperazine • • Ranitdine • • Enflurane • • Halothane • • Katamine • • Herbals/Nutraceuticals • • Echinacea • • Garic • • Grapefruit juice • • Milk thistie • • Seville orange juice • • St John's Wort • • Vitamin E • • Ilicit/Recreational • • Alcohol • • Gamma-hydroxybutyrate • • Marijuan • • MbtAmphetamine • • Interferon alfa-2a • • <td></td> <td>•</td> <td>•</td> <td>•</td>		•	•	•
Lansoprazole				
Loperamide Omeprazole Omegrazole Ondansetron Prochlorperazine Rantidine General Anaesthetics Enflurane Halothane Ketamine Halothane Ketamine Halothane Ketamine Harotals/Nutraceuticals Echinacea Gartic Grapefruit juice Harotals/Nutraceuticals Echinacea Gartic Grapefruit juice Hilk thistle Seville orange juice St John's Wot Vitamin E Harotals/Nutrate Halotane MDMA ('Ecstasy') Methamphetamine MDMA ('Ecstasy') Methamphetamine Harotals/Ressants Ciclosporin Mpcophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus Coral Ant-diabetics Gilpizide Seville Constantin		- <mark>-</mark>		- i
Metoclopramide Omeprazole Ondansetron Prochlorperazine Ranitidine Enflurane Enflur		•	•	•
Ondansetron • • Prochlorperazine • • Ranitidine • • General Anaesthetics • • Enflurane • • Halothane • • Ketamine • • Berbals/Nutraceuticals • • Echinacea • • Garlic • • Grapefruit juice • • Milk thistie • • Seville orange juice • • St.John's Wort • • Vitamin E • • Illicit/Recreational • • Alcohol Gamma-hydroxybutyrate • • Mathamphetamine • • • Interferon alpha • • • Interferon alfa-2a • • •	Metoclopramide	•	•	•
Prochlorperazine Ranitidine General Anaesthetics Enflurane Halothane Ketamine Halothane Ketamine Herbals/Nutraceuticals Echinacea Garic Graperiut juice Milk thistle Graperiut juice St John's Wort Vitamin E Hilicit/Recreational Alcohol Gamma-hydroxybutyrate Marijuana MDMA ("Ecstasy") Methamphetamine Hinterleukin 2 Peginterferon alfa-2a Hydroxyurea Interferon alfa-2a Lorvastatin Lorostatin Lorvastatin Lorvastatin Drat Att-diabetics Gilpizide Metgrain Gamina-hydroxybutyrate Atorvastatin Coral Ant-diabetics Gilpizide Dexamethasone Ethinylestradol Megestrol acetate Nandrolone Progesterone/Progestogen Gamina-hydroxybutyrate Atorvastatin Coral Ant-diabetics Gilpizide Coral Ant-diabetics Coral Ant-diabe		•	•	•
Ranitidine • • General Anaesthetics • • Enflurane • • • Halothane • • • Ketamine □ □ □ □ Herbals/Nutraceuticals □ □ □ □ Echinacea □ □ □ □ □ Garic □ □ □ □ □ □ Garic □				
General Anaesthetics Enflurane Halothane Ketamine Herbals/Nutraceuticals Echinacea Garic Grapefruit juice Milk thistic Sevile orange juice St John's Wort Vitamin E Milcit/Recreational Alcohol Garma-hydroxybutyrate Marijuana MDMA ("Ecstasy") Methamphetamine Interferon alfa-2a Hydroxyurea Hydroxyurea Mycophenolate Sirolimus Tacrolimus Lipid Lowering Agents Atorvastatin Ciclosporin Fluvastatin Genfibrizil Lovastatin Ciclipizate Fluvastatin Gipizide Farolibrizil Lovastatin Ciclipizate Fluvastatin Morti-diabetics Giglipizone Tarolibrizil Lovastatin Deamethisone Ethinylestradiol		- <u>-</u>	· .	- - -
Enflurane Halothane Ketamine Halothane Ketamine Horbals/Nutraceuticals Echinacea Garic Grapefruit juice Grapefruit juice Milk thistle Gamma-hydroxybutyrate Marijuana MDMA ("Ecstasy") Methamphetamine Modulators Hydroxyurea Interferon alfa-2a Hydroxyurea Interferon alfa-2a Hydroxyatatin Ciclosporin Ciclospo				
Ketamine Image: Constraint of the second		•	•	•
Herbals/Nutraceuticals Echinacea Garlic I Garlic I Garlic I Grapefruit juice I Milk thistle I St John's Wort I Vitamin E I Illicit/Recreational Alcohol Image I Gamma-hydroxybutyrate Image I MDMA ("Ecstasy") Image I Interleukin 2 Image I Peginterferon alpha Interleukin 2 Interleukin 2 Image I Peginterferon alpha Image I Interleukin 2 Image I Interleukin 2 Image I Taroolinus Image I Interleukin 2 Image I Interleukin 2 Imag		•	•	•
Echinacea Image: Constraint of the second secon				
Milt thistle Image interference St John's Wort Image interference Illicit/Recreational Alcohol Alcohol Image interference Gamma-hydroxybutyrate Image interference Marijuana Image interference MDMA ("Ecstasy") Image interference Interferen alpha Interferen alpha Interferen alpha I		_	_	_
Milt thistle Image interference St John's Wort Image interference Illicit/Recreational Alcohol Alcohol Image interference Gamma-hydroxybutyrate Image interference Marijuana Image interference MDMA ("Ecstasy") Image interference Interferen alpha Interferen alpha Interferen alpha I		- H		- H
Milk thistle Image juice Image juice St John's Wort Image juice St John's Wort Image juice St John's Wort Image juice Vitamin E Image juice Alcohol Image juice Gamma-hydroxybutyrate Image juice Marijuana Image juice MbMA ("Ecstasy") Image juice Interferon alpha Image juice <tr< td=""><td></td><td>- 🖡 -</td><td>· 🖡 ·</td><td></td></tr<>		- 🖡 -	· 🖡 ·	
St. John's Wort • Vitamin E • Alcohol • Gamma-hydroxybutyrate • Maina-hydroxybutyrate • MDMA ("Ecstasy") • Methamphetamine • Immune Modulators Hydroxyurea • Interferon alpha • Interferon alpha • Interferon alpha • Interferon alfa-2a • Peginterferon alfa-2a • Immunosuppressants □ Ciclosporin □ Mycophenolate • Sirolimus □ Lipid Lowering Agents • Atorvastatin □ Gemfibrizil • Lovastatin □ Pravastatin □ Simvastatin □ Simvastatin □ Oral Anti-diabetics □ Gilpizide □ □ Metformin ● □ Metgestrol acetate • • Nandrolone □ □				
Vitamin E • • Illicit/Recreational Alcohol • Alcohol • • Gamma-hydroxybutyrate • • Marijuana • • MDMA ("Ecstasy") • • Methamphetamine • • Immune Modulators • • Hydroxyurea • • Interferon alpha • • Interferonal • • Giofibrate • • <t< td=""><td></td><td>•</td><td>•</td><td>•</td></t<>		•	•	•
Illicit/Recreational Alcohol Gamma-hydroxybutlyrate Marinuana MDMA ("Ecstasy") Methamphetamine Immune Modulators Hydroxyurea Interleukin 2 Peginterferon alfa-2a Peginterferon alfa-2a Interleukin 2 Interleukin 2 Interleukin 2 Interleukin 2 Interleukin 2 Interleukin 3 Interleukin 4 Interleuki		•		•
Alcohol Gamma-hydroxybutyrate Marijuana MDMA ("Ecstasy") Methamphetamine Immune Modulators Hydroxyurea		•	•	•
Gamma-hydroxybutyrate Marijuna MDMA (*Ecstasy*) MDMA (*Ecstasy*) MDMA (*Ecstasy*) MDMA (*Ecstasy*) Mdthamphetamine M		•	•	•
MDMA ("Ecstasy") • Methamphetamine • Immune Modulators • Hydroxyurea • • Interferon alpha • • Metornins • • Taroolinus • • Intorvastatin • • Ciofibrate • • Fenofibrate • • Furoids • • Resuvastatin • • Simvastatin • • Oral Anti-diabetics • • <tr< td=""><td></td><td>÷</td><td>•</td><td>•</td></tr<>		÷	•	•
Methamphetamine Immune Modulators Hydroxyurea Interleukin 2 Peginterferon alfa-2a Immunosuppressants Ciclosporin Ciclosporin Mycophenolate Sirolimus Control Control Control Control Control Contro 		•	•	•
Immune Modulators Hydroxyurea Hydroxyurea Hydroxyurea			. 🔶 .	. •
Hydroxyurea Interleukin 2 Interleukin 2 Peginterferon alfa-2a Peginterferon alfa-2 Peginterfer		<u> </u>	•	•
Interferon alpha Interferon alfa-2a Peginterferon alfa-2a Peginterferon alfa-2a Ciclosporin Ciclosporin Mycophenolate Sirolimus Ciclofibrate Atorvastatin Cicliforate Fenofibrate Fenofibrate Fenofibrate Fluvastatin Comfinitat Cicliforate Fluvastatin Comfibrize Cicliforate Fluvastatin Comfibrize Cicliforate				•
Interleukin 2 Peginterferon alfa-2a Peginte		· 🗼 ·	· 🗼 ·	- 🗼 - I
Immunosuppressants Ciclosporin		•	•	•
Ciclosporin Mycophenolate Tacrolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus Atorvastatin Clofibrate Fluvastatin Clofibrate Fluvastatin Combinizil Coversity		•	•	•
Mycophenolate Sirolimus Continuus Con		_	_	_
Sirolimus				
Tarolimus Image: Constraint of the second secon		- -		- <u>-</u>
Lipid Lowering Agents Atorvastatin Clofibrate Fenofibrate Gemfibrizil Covastatin Gemfibrizil Covastatin Cova				
Atorvastatin Image: Confibrate Image: Confibrate Fenofibrate Image: Confibrate Image: Confibrate Fluvastatin Image: Confibrate Image: Confibrate Gemfibrizil Image: Confibrate Image: Confibrate Lovastatin Image: Confibrate Image: Confibrate Pravastatin Image: Confibrate Image: Confibrate Oral Anti-clabetics Image: Confibrate Image: Confibrate Gilpizide Image: Confibrate Image: Confibrate Metformin Image: Confibrate Image: Confibrate Steroids Image: Confibrate Image: Confibrate Dexamethasone Image: Confibrate Image: Confibrate Ethinylestradiol Image: Confibrate Image: Confibrate Nandroione Image: Confibrate Image: Confibrate Prodiscolore Image: Confibrate Image: Confibrate Nandroione Image: Confibrate Image: Confibrate Prodiscolore Image: Confibrate Image: Confibrate Stanazoloi Image: Confibrate Image: Confibrate Testosterone Image: Confibrate Image: Confibrate				
Fendibrate Fluvastatin Gemfibrizil Constant Con	Atorvastatin			
Fluvastatin Image: Constraint of the second sec		•	•	•
Gemfbrizil Lovastatin Pravastatin Cossuvastatin Coral Anti-diabetics Glipizide Metformin Rosiglitazone Tolbutamide Steroids Dexamethasone Ethinylestradiol Megestrol acetate Nandrolone Prednisolone Prednisolone Testosterone Devention				
Lovastatin Pravastatin Pravamethasone Ethinylestradiol Megestrol acetate Nandrolone Progesterone/Progestogen Stanazol Testosterone Predisole Pravastatol Pravastat		-	-	-
Rosuvastatin • • Simvastatin • • Oral Anti-diabetics • • Glipizide • • • Metformin • • • • Rosiglitazone • • • • • Steroids •	Lovastatin			
Simvastatin Oral Anti-diabetics Glipizide Metformin Rosiglitazone Tolbutamide Steroids Dexamethasone Ethinylestradiol Megestrol acetate Nandrolone Prednisolone Prednisolone Progesterone/Progestogen Stanazolol Testosterone		•		+
Oral Anti-diabetics Glipizide Metformin Rosiglitazone Tolbutamide Steroids Ethinylestradiol Megestrol acetate Nandrolone Prednisolone Progesterone/Progestogen Stanazolol Testosterone		÷	÷	•
Glipizide Image: Construct of the second				
Metformin Rosiglitazone Tolbutamide Tolbutamide Steroids Steroids Ethinylestradiol Ethinylestradiol Megestrol acetate Nandrolone Prednisolone Progesterone/Progestogen Stanazolol Etastosterone 			P	
Tolbutamide □ □ Steroids □ □ Dexamethasone □ □ Ethinylestradiol ◆ □ Megestrol acetate ◆ ◆ Nandrolone ● ● Prednisolone □ □ Progesterone/Progestogen □ □ Stanazolol □ □ Testosterone □ □		•	•	•
Steroids		•	•	
Dexamethasone Ethinylestradiol Megestrol acetate Nandrolone Prednisolone Progesterone/Progestogen Stanazole Testosterone				
Ethinylestradiol				
Megestrol acetate Mandrolone Prednisolone Progesterone/Progestogen C C Stanazolol C C Testosterone		-		
Nandrolone Prednisolone Progesterone/Progestogen Calification Calification		•	•	•
Prednisolone □ □ □ Progesterone/Progestogen □ □ □ Stanazolol □ □ □ Testosterone □ □ □		•	•	•
Stanazolol Testosterone	Prednisolone			
Testosterone				
				_

Full information available at www.hiv-druginteractions.org Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

© Liverpool HIV Pharmacology Group, University of Liverpool Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF

Although great care has been taken in compiling and checking that this information is accurate, the University of Liverpool, and its servants or agents shall not be responsible or in anyway liable for the continued currency of the information or for any errors, omissions or inaccuracies in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

ATIC News, January 2006

Nevirapine (Viramune®)

Key to abbreviations

NVP

DLV Delavirdine (Rescriptor®) EFV Efavirenz (Sustiva®, Stocrin®)

Send your queries to queries@atic.idi.co.ug or call 031- 307271/307245/307258

Adults and children estimated to be living with **HIV** in **2005**





ATIC News is published by The Infectious Diseases Institute, P. O. Box 22418, Kampala, Tel (Admin): 256-41-542352-542283